Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Despite overall improvements in outcomes of diffuse large B-cell lymphoma (DLBCL),
approximately one-third of patients will develop relapsed/refractory disease that remains a …

Background Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few
treatment options. We aimed to establish the safety and recommended phase 2 dose of …

Purpose For patients with relapsed or refractory aggressive lymphoma, we hypothesized
that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as …

Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell
transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma …

Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …

Chemotherapy-induced neutropaenia is a major risk factor for infection-related morbidity
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …

Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma
(DLBCL), variably express CD30. This phase 2, open-label study evaluated the efficacy of …

Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination
with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by …

Despite progress in the upfront treatment of diffuse large B cell lymphoma (DLBCL), patients
still experience relapses. Salvage chemotherapy followed by autologous stem cell …